Ocrevus (Ocrelizumab)

Ocrelizumab is a monoclonal antibody that binds to the CD20 protein on B‑lymphocytes. This binding triggers immune mechanisms that destroy CD20‑positive B cells, reducing the autoimmune activity that contributes to the demyelination and neuro‑inflammation characteristic of multiple sclerosis.

The dosing schedule for Ocrevus is determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. The prescriber will decide the initial and subsequent infusion intervals in accordance with approved labeling and local guidelines.

The safety of ocrelizumab in pregnancy and lactation has not been fully established. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To request Ocrevus, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Ocrevus is a B‑cell depleting monoclonal antibody, distinct from interferon‑based or oral sphingosine‑1‑phosphate modulators. Compared with those classes, it offers a different mechanism, longer dosing intervals, and a specific safety profile that includes infusion‑related reactions and infection risk, which clinicians weigh against efficacy benefits.

Ocrevus must be stored refrigerated between 2 °C and 8 °C. Keep the vials in the original packaging, protect them from light, and do not freeze or shake. If temporary temperature excursions occur, follow the manufacturer’s guidance before administration.

Ocrevus is given as an intravenous infusion under medical supervision. The first dose is split into two infusions two weeks apart, followed by a single infusion every six months. Administration settings must have facilities to manage potential infusion reactions.

Serious risks include opportunistic infections such as hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML), severe infusion reactions, cardiac events, and rare cases of malignancy. Patients should be monitored regularly for signs of infection, cardiac symptoms, and abnormal laboratory values.

Ocrevus is contraindicated in individuals with known hypersensitivity to ocrelizumab or any of its excipients, and in patients with active severe infections. Live vaccines should not be administered during treatment, and caution is advised for those with compromised immune systems or uncontrolled cardiac disease.